China Nuokang Bio-Pharmaceutical Inc. is a biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. As of December 31, 2009, the Company sold a portfolio of 14 products, including three principal products: Baquting, its bleeding control product; Aiduo, its cardiovascular stress imaging agent, and Aiwen, an anti-arrhythmic agent. It has also entered into an agreement for the marketing and distribution in China of Kaitong, an intravenous injectable lipid emulsion of vasodilator alprostadil for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis. As of December 31, 2009, its product pipeline included four product candidates under development for bleeding control and hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention.

China Nuokang Bio-Pharmaceutical Inc.  is a leading biopharmaceutical company in China focused on the research, development, manufacture, marketing and sales of hospital-based medical products. The Company provides a diversified portfolio of products across more than 2,400 hospitals in China. Nuokang's principal products include Baquting(R), China's leading hemocoagulase product by market share, and Kaitong(R), a lipid emulsion alprostadil product for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis. The Company's product pipeline includes product candidates under development in hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention.